UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients

International journal of hematology, 2021-06, Vol.113 (6), p.777-784

2021

Volltextzugriff (PDF)

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

The American journal of cardiology, 2014, Vol.113 (1), p.76-83

2014

Volltextzugriff (PDF)

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia

The American journal of cardiology, 2008-03, Vol.101 (5), p.625-630

2008

Volltextzugriff (PDF)

Lipid-modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-density Lipoprotein Cholesterol

The American journal of cardiology, 2017-02, Vol.119 (3), p.388-396

2017

Volltextzugriff (PDF)

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome

Journal of the American College of Cardiology, 2016-02, Vol.67 (4), p.353-361

2016

Volltextzugriff (PDF)

Effectiveness and Safety of Laropiprant on Niacin-Induced Flushing

The American journal of cardiology, 2012-09, Vol.110 (6), p.817-822

2012

Volltextzugriff (PDF)

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial

Journal of the American College of Cardiology, 2016-02, Vol.67 (4), p.353-361

2016

Volltextzugriff (PDF)

Pooled analysis of two randomized, open-label studies comparing the effects of nomegestrol acetate/17β-estradiol and drospirenone/ethinyl estradiol on bleeding patterns in healthy women

Contraception (Stoneham), 2017-04, Vol.95 (4), p.390-397

2017

Volltextzugriff (PDF)

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

Clinical cancer research, 2021-04, Vol.27 (7), p.1923-1931

2021

Volltextzugriff (PDF)

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

The Lancet. Haematology, 2019-09, Vol.6 (9), p.e459-e469

2019

Volltextzugriff (PDF)

Lack of Effect of Antacids on Single-Dose Pharmacokinetics of Etoricoxib

Journal of clinical pharmacology, 2007-10, Vol.47 (10), p.1342-1346

2007

Volltextzugriff (PDF)

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.243-243

2022

Volltextzugriff (PDF)

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix

The American journal of cardiology, 2008-03, Vol.101 (5), p.625-630

2008

Volltextzugriff (PDF)

Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas

Cancer, 1994-07, Vol.74 (2), p.697-702

1994

Volltextzugriff (PDF)

Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.427-427

2020

Volltextzugriff (PDF)

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS8070-TPS8070

2016

Volltextzugriff (PDF)

KEYNOTE-062: Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4138-TPS4138

2016

Volltextzugriff (PDF)

KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.TPS185-TPS185

2016

Volltextzugriff (PDF)

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study

Journal of clinical oncology, 2019-06, Vol.37 (18_suppl), p.LBA4007-LBA4007

2019

Volltextzugriff (PDF)

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8021-8021

2018

Volltextzugriff (PDF)

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

Journal of cardiovascular pharmacology and therapeutics, 2014-11, Vol.19 (6), p.543-549

2014

Volltextzugriff (PDF)

EFFECTS OF LONGER-TERM TREATMENT WITH ANACETRAPIB ON SAFETY PARAMETERS, LIPIDS, AND PLASMA DRUG CONCENTRATIONS IN THE DEFINE TRIAL

Journal of the American College of Cardiology, 2014-04, Vol.63 (12), p.A1449-A1449

2014

Volltextzugriff (PDF)

Abstract 8824: Following Stable Therapy with Extended Release Niacin/Laropiprant, Continued Extended Release Niacin/Laropiprant Use Reduced Flushing versus Extended Release Niacin Alone in Dyslipidemic Patients

Circulation (New York, N.Y.), 2011-11, Vol.124 (suppl_21)

2011

Volltextzugriff (PDF)

The importance of clinical staging of minor salivary gland carcinoma

The American journal of surgery, 1991-10, Vol.162 (4), p.330-336

1991

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(37)
magazinearticle
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia

Lipid-modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-density Lipoprotein Cholesterol

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome

Effectiveness and Safety of Laropiprant on Niacin-Induced Flushing

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial

Pooled analysis of two randomized, open-label studies comparing the effects of nomegestrol acetate/17β-estradiol and drospirenone/ethinyl estradiol on bleeding patterns in healthy women

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Lack of Effect of Antacids on Single-Dose Pharmacokinetics of Etoricoxib

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix

Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas

Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM)

KEYNOTE-062: Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

EFFECTS OF LONGER-TERM TREATMENT WITH ANACETRAPIB ON SAFETY PARAMETERS, LIPIDS, AND PLASMA DRUG CONCENTRATIONS IN THE DEFINE TRIAL

Abstract 8824: Following Stable Therapy with Extended Release Niacin/Laropiprant, Continued Extended Release Niacin/Laropiprant Use Reduced Flushing versus Extended Release Niacin Alone in Dyslipidemic Patients

The importance of clinical staging of minor salivary gland carcinoma

Suchergebnisse filtern